Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
COHANCE Stock Chart & Stats
₹891.10
₹6.60(0.60%)
At close: 4:00 PM EST
₹891.10
₹6.60(0.60%)
Day’s Range― - ―
52-Week Range₹267.85 - ₹1,246.85
Previous CloseN/A
VolumeN/A
Average Volume (3M)116.47K
Market Cap
₹115.50B
Enterprise Value₹119.01B
Total Cash (Recent Filing)₹4.03B
Total Debt (Recent Filing)₹4.51B
Price to Earnings (P/E)92.3
Beta0.56
Next Earnings
May 28, 2026EPS Estimate
1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding382,567,140
10 Day Avg. Volume24,499
30 Day Avg. Volume116,469
Financial Highlights & Ratios
PEG Ratio-9.48
Price to Book (P/B)16.23
Price to Sales (P/S)23.00
P/FCF Ratio207.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.83
Revenue Forecast (FY)₹23.84B
Bulls Say, Bears Say
Bulls Say
Robust Revenue GrowthNear-100% reported revenue growth indicates the company is successfully scaling CDMO programs and winning business. Durable top-line expansion improves fixed-cost absorption, funds reinvestment into capacity and R&D, and strengthens bargaining power with regulator-focused customers over the medium term.
CDMO/CRAMS Business Model And CapabilitiesA focused CDMO model serving complex small-molecule APIs creates structural demand from innovator pharma and biotech clients. Technical know-how and regulatory-compliant manufacturing are high barriers to entry, supporting recurring project pipelines and long-term client stickiness as programs move toward commercialization.
Healthy Balance Sheet And Strong ROELow leverage and a solid equity base provide financial stability and flexibility to fund capex or weather regulatory delays without overreliance on external financing. Strong ROE signals effective capital deployment, supporting sustainable investment in capacity and the ability to pursue strategic CDMO opportunities.
Bears Say
EPS Contraction / Declining Net IncomeA large negative EPS growth rate signals margin pressure or one-off hits that reduce earnings power. Sustained EPS contraction can limit internal funding for expansion, lower earnings resilience to project delays, and may reflect operational or pricing challenges that impair long-term profitability.
Weakened Free Cash FlowDeclining free cash flow reduces capacity to self-fund growth, pay down debt, or return capital. Higher capex with falling operating cash makes the business more reliant on external financing for expansion, which can constrain strategic flexibility and slow capacity-driven revenue realization over the medium term.
Revenue Dependence On Customer Program ProgressionCDMO revenues are lumpy and tied to clients advancing programs through development and commercialization. Delays, trial failures, or lost renewals create material revenue volatility. High customer concentration magnifies this risk, making long-term revenue visibility and predictability weaker than in diversified manufacturing businesses.
Suven Pharmaceuticals Ltd. News
COHANCE FAQ
What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?
Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹1246.85 in the past 12 months.
What is Suven Pharmaceuticals Ltd.’s market cap?
Suven Pharmaceuticals Ltd.’s market cap is ₹115.50B.
When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?
Suven Pharmaceuticals Ltd.’s upcoming earnings report date is May 28, 2026 which is in 57 days.
How were Suven Pharmaceuticals Ltd.’s earnings last quarter?
Suven Pharmaceuticals Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.975 earnings per share for the quarter, missing the consensus estimate of ₹2.693 by -₹1.718.
Is Suven Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Suven Pharmaceuticals Ltd. pay dividends?
Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here
What is Suven Pharmaceuticals Ltd.’s EPS estimate?
Suven Pharmaceuticals Ltd.’s EPS estimate is 1.58.
How many shares outstanding does Suven Pharmaceuticals Ltd. have?
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.
What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?
Suven Pharmaceuticals Ltd. reported an EPS of ₹0.975 in its last earnings report, missing expectations of ₹2.693. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:COHANCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suven Pharmaceuticals Ltd.
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as Suven Pharmaceuticals Limited and underwent a rebranding following its merger with Cohance Lifesciences, effective May 1, 2025.
Technical Analysis
Ajanta Pharma Limited
―
Biocon Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―